Innovent (@Innovent_2011) header
Innovent (@Innovent_2011) profile picture

To empower patients worldwide with affordable, high-quality biopharmaceuticals

Suzhou Jiangsu, P. R. China
Joined July 2021
Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)Photo by Innovent (@Innovent_2011)
Innovent is pleased to share that our partner @Takeda has been granted SAKIGAKE designation by Japan's Ministry of Health, Labour and Welfare for arcotatug tavatecan (IBI343/TAK-921), our CLDN18.2-targeted ADC, in previously treated CLDN18.2-positive advanced #GastricCancer.
165
Innovent’s Partner Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired en.innoventbio.com/Investors…
172
Innovent Showcases Preclinical Data of its First-in-Class IL-6 x TL1A Bispecific Antibody at ACR Convergence 2026
132
Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy prnewswire.com/news-releases…
188
We're honored to share that Innovent Biologics has been named Company of the Year at the 13th China Healthcare Summit* in Shanghai, held November 2 to 4, 2026. The award recognizes Innovent's strengths in business development, R&D, and commercialization.
191
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma en.prnasia.com/releases/glob…
439
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS en.prnasia.com/releases/glob…
471
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC en.prnasia.com/releases/glob…
111
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer en.prnasia.com/releases/glob…
105
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein en.prnasia.com/releases/glob…
111
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease #ThyroidEyeDisease #Ophthalmology #InnoventBiologics
161
This World Heart Day, we join the World Heart Federation in calling for heart health that is equitable and accessible for everyone. Don't miss a beat.#DontMissABeat #WorldHeartDay
135
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
146
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC.
154
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting prnewswire.com/news-releases…
140
Innovent's Suzhou Manufacturing Base Receives EMA GMP Certification  140,000L active production capacity ~20% of China's total biologics capacity Manufacturing standards that meet NMPA, FDA and EMA requirements
161
Innovent Biologics named 2026 China Outstanding Employer by China Top Employers Institute, our first‑ever honor. Committed to talent & inclusive culture. Grateful to all colleagues. Forward for our people and biopharma.
1
135
Innovent Announces 2026 Interim Results and Business Updates. Transforming from Regional Leader to Global Premier:A Clear Strategic Path for Growth and Globalization.prnewswire.com/news-releases…
1
142